• Biodesix Presents Data From Three Studies at AACR Annual Meeting

    April 5, 2017 New data on liquid biopsy genomic tests, including multiplexed genomic assays; evaluation of biological processes underlying mass spectrometry proteomic assays of human serum April 5, 2017, Boulder, Colorado… Biodesix is presenting three studies that support the company’s multi-omic capabilities and provide insight into the biology of classifiers developed with Deep MALDI™ mass spectrometry and the Diagnostic ... Read more
  • New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

    April 3, 2017 BOULDER, Colo., April 3, 2017 — Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC) reduces the aggregate costs of end-of-life treatment while improving survival and quality of life. The data were presented at the American College of Medical Quality (MQ2017) annual ... Read more
  • Biodesix Announces Data To Be Presented at AACR Annual Meeting 2017

    March 28, 2017 New data on genomic tests and single-reaction, multiplexed genomic assays; evaluation of biological processes via mass spectrometry of human serum March 28, 2017, Boulder, Colorado…Biodesix, Inc. will present three posters summarizing new data from research evaluating the company’s genomic tests and its PSEA (protein set enrichment analysis) platform at the American Association for Cancer Research (AACR) ... Read more
  • New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

    March 22, 2017 A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer. Read more
  • Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

    March 20, 2017 Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients   Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in immuno-oncology. These blood-based tests, which were developed on Biodesix’s proprietary Diagnostic Cortex™ platform, may identify patients who derive significant benefit from anti-PD-1 monotherapy ... Read more
  • Biodesix® and Progenetics Announce Distribution Agreement for Israel

    March 9, 2017 March 9, 2017, Boulder, Colorado…Biodesix, Inc. (Boulder, CO, USA) and Progenetics LTD (Tel Aviv, Israel) announced today that they have entered into an international agreement where Progenetics will market and distribute kits for Biodesix’s GeneStrat® and VeriStrat® liquid biopsy tests for patients with non-small cell lung cancer (NSCLC). Both tests are now available for clinical use ... Read more
  • Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

    February 27, 2017 Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1 ddPCR Assay Measures mRNA Expressions from Immune and Cancer Cell; Key Step In Development of Immunotherapy Test New data from Biodesix® evaluating an assay in development demonstrated the potential to measure circulating PD-L1 through mRNA in blood through multiplexed droplet digital™ PCR (ddPCR, Bio-Rad, Inc.) detection. The assay uses proprietary ... Read more
  • Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

    February 15, 2017 Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1 ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells   Poster Title: Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.   Poster Session Date/Time: February 24, 11:30AM – 1:00PM; 5:30PM-6:30PM   Presenting Author: Hestia Mellert, Ph.D Corresponding Author: Gary Pestano, Ph.D   Location: Regency Ballroom, Hyatt ... Read more
  • Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

    February 2, 2017 Actionable mutation results from a single blood draw, 72 hour turnaround time   February 2, 2017, Boulder, CO….Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRAS, BRAF mutations; and EML4-ALK fusions. GeneStrat is a non-invasive, blood test ... Read more
  • Clin-TOF Successfully Integrated into VeriStrat® Workflow

    January 26, 2017 Study Results, Presented at MSACL, Advance Biodesix®/Bioyong Agreement Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat® test in Greater China. The data were presented in a poster at the ninth annual conference of the Association for ... Read more